REPORTS

Let’s Pullulate and Expand Your Business

Insomnia Drugs Market - Global Professional Analysis and Forecast to 2026

Oct 11, 2019  |  170 PAGES  |  REPORT CODE: CMM204815
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Insomnia Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.6% during the forecast period.

This report presents the market size and development trends by detailing the Insomnia Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Insomnia Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Insomnia Drugs industry and will help you to build a panoramic view of the industrial development.

Insomnia Drugs Market, By Type:

  • Pills Product

  • Capsules Product

  • Others

Insomnia Drugs Market, By Application:

  • Adults

  • Kids

Some of the leading players are as follows:

  • Paratek Pharmaceuticals

  • SkyePharma

  • Meda

  • Eisai

  • Dainippon Sumitomo

  • Sanofi

  • Pfizer

  • Johnson & Johnson

  • Takeda

  • ECR Pharmaceuticals (Valeant)

  • Purdue Pharma

  • Merck

  • Minerva Neurosciences

  • Vanda Pharmaceuticals

  • Somnus Therapeutics

  • Flynn Pharma

  • Neurim

  • Astellas

  • Pernix Therapeutics

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Insomnia Drugs Market: Technology Type Analysis

  • 4.1 Insomnia Drugs Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Insomnia Drugs Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Pills Product

    • 4.3.2 Capsules Product

    • 4.3.3 Others

5 Insomnia Drugs Market: Product Analysis

  • 5.1 Insomnia Drugs Product Market Share Analysis, 2018 & 2026

  • 5.2 Insomnia Drugs Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Insomnia Drugs Market: Application Analysis

  • 6.1 Insomnia Drugs Application Market Share Analysis, 2018 & 2026

  • 6.2 Insomnia Drugs Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 Adults

    • 6.3.2 Kids

7 Insomnia Drugs Market: Regional Analysis

  • 7.1 Insomnia Drugs Regional Market Share Analysis, 2018 & 2026

  • 7.2 Insomnia Drugs Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Paratek Pharmaceuticals

    • 9.1.1 Paratek Pharmaceuticals Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 SkyePharma

    • 9.2.1 SkyePharma Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Meda

    • 9.3.1 Meda Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Eisai

    • 9.4.1 Eisai Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Dainippon Sumitomo

    • 9.5.1 Dainippon Sumitomo Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Sanofi

    • 9.6.1 Sanofi Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Pfizer

    • 9.7.1 Pfizer Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Johnson & Johnson

    • 9.8.1 Johnson & Johnson Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Takeda

    • 9.9.1 Takeda Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 ECR Pharmaceuticals (Valeant)

    • 9.10.1 ECR Pharmaceuticals (Valeant) Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Purdue Pharma

    • 9.11.1 Purdue Pharma Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Merck

    • 9.12.1 Merck Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Minerva Neurosciences

    • 9.13.1 Minerva Neurosciences Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Vanda Pharmaceuticals

    • 9.14.1 Vanda Pharmaceuticals Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Somnus Therapeutics

    • 9.15.1 Somnus Therapeutics Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Flynn Pharma

    • 9.16.1 Flynn Pharma Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 Neurim

    • 9.17.1 Neurim Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Astellas

    • 9.18.1 Astellas Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Pernix Therapeutics

    • 9.19.1 Pernix Therapeutics Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

 

The List of Tables and Figures (Totals 73 Figures and 134 Tables)

  • Figure Pills Product Insomnia Drugs market, 2015 - 2026 (USD Million)

  • Figure Capsules Product Insomnia Drugs market, 2015 - 2026 (USD Million)

  • Figure Others Insomnia Drugs market, 2015 - 2026 (USD Million)

  • Figure Adults market, 2015 - 2026 (USD Million)

  • Figure Kids market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Insomnia Drugs market, by country, 2015 - 2026 (USD Million)

  • Table North America Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table North America Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table North America Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Canada Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Canada Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Europe Insomnia Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Europe Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Europe Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Europe Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Germany Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Germany Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table France Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table France Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Italy Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Italy Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Spain Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Spain Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Insomnia Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table China Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table China Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Japan Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Japan Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table India Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table India Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Insomnia Drugs market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table MEA Insomnia Drugs market, by country, 2015 - 2026 (USD Million)

  • Table MEA Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table MEA Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table MEA Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Insomnia Drugs market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Insomnia Drugs market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Insomnia Drugs market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Paratek Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table SkyePharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Meda Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eisai Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Dainippon Sumitomo Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Sanofi Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Johnson & Johnson Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Takeda Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table ECR Pharmaceuticals (Valeant) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Purdue Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Minerva Neurosciences Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Vanda Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Somnus Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Flynn Pharma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Neurim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Astellas Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pernix Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top